TWM577734U - Capsule filled with medicine powder for pets - Google Patents

Abstract

A capsule containing a pet powder, comprising: a capsule container body surrounding a housing space; a pet powder, which is accommodated in the housing space and wrapped by the capsule container body, wherein the pet medicine The powder comprises 50% to 90% by weight of a flavonoid compound and 10% to 50% by weight of D-limonene, the flavonoid compound is selected from the group consisting of naringin, hesperidin, neohesperidin, rutin, orange A group consisting of sulphate, chuanshensu, quercetin, anthraquinone, eriocitrin, sacred licorice, and citrus.

Description

Capsule containing pet powder

This creation is about a capsule containing pet powder.

Due to the characteristics of hair and skin, pets can cause pathogens such as bacteria, fungi, viruses and parasites to easily grow on their hair and skin surface, resulting in a very high incidence of skin diseases in pets. There are many causes of pet skin diseases: infections of microorganisms such as bacteria and fungi; skin allergies caused by fleas and tick bites; parasitic infections such as hairy worms and mites; lack of nutrition; improper care and feeding environment. Although the etiology is different, the clinical symptoms are similar. Most of the symptoms are facial, neck, back, abdomen and tail root. The skin has flushing, scaling, crusting, itching, hair loss and other symptoms. When the pathogen is mixed, pustules and exudates appear, pigmentation, papules or small nodules. The symptoms are complicated, the course of disease is long, and it is difficult to diagnose and treat.

Skin diseases can cause itching and hair loss, which can seriously affect the appearance and health of pets and even lead to death. However, at present, most of the common therapeutic drugs for pets suffering from skin diseases are chemical synthetic products, and the toxicity and side effects are large, and many microorganisms such as bacteria and fungi have developed drug resistance, which increases the difficulty in treating skin diseases.

In addition, pets are not human, and it is extremely difficult to feed medicines. Once the medicine has begun to dissolve in the pet's mouth and produces bitterness, the pet immediately spits out the medicine and it is more difficult to feed again. Therefore, it is necessary to find a way to treat the pet medicine. Feeding convenience and effectiveness are improved.

The main purpose of the present invention is to provide a capsule containing a pet powder, which has good anti-microbial and anti-inflammatory effects, low toxicity and no side effects, and can protect the powder and ensure complete absorption.

In order to achieve the above object, the present invention provides a capsule containing a pet powder, comprising a capsule container body and a pet powder.

The capsule container body surrounds an accommodating space; the pet powder is contained in the accommodating space and is wrapped by the capsule container body, wherein the pet powder comprises 50% to 90% by weight of a flavonoid compound With 10% to 50% by weight of D-limonene, the flavonoid compound is selected from the group consisting of naringin, hesperidin, neohesperidin, rutin, erythroside, nobiletin, quercetin, and quercetin. , a group consisting of eriocitrin, new sage citricin, and citrus.

Therefore, the present invention has good antibacterial, antifungal and anti-inflammatory effects, and has low toxicity without side effects, and is suitable for the treatment of bacterial, fungal and parasitic infectious skin diseases of various pets, and is filled by a capsule container. It is good for prescription, application, and easy to feed, and it also ensures that the powder remains intact until it reaches the pet's stomach.

10‧‧‧ capsule container body

101‧‧‧First housing

1011‧‧‧First joint

102‧‧‧ second housing

1021‧‧‧Second joint

11‧‧‧ accommodating space

20‧‧‧Pet powder

Figure 1 is a perspective view of the creation.

Figure 2 is a cross-sectional view of the A-A of the present creation.

The following is a description of possible implementations of the present invention by way of example only, and is not intended to limit the scope of the creation of the present invention.

Referring to FIG. 1 and FIG. 2, the present invention provides a capsule containing a pet powder, comprising a capsule container body and a pet powder.

The capsule housing body 10 is composed of a first housing 101 and a second housing 102. The first housing 101 and the second housing 102 respectively have an opening, and the first housing 101 is farther away from the opening thereof. One end is hemispherical and the other part is round tubular. The second housing 102 is hemispherical from one end away from the opening and the other part is round tubular. The first housing 101 has a first joint portion 1011 beside the opening thereof. The second housing 102 has a second engaging portion 1021 adjacent to the opening thereof, and the first housing 101 and the second housing 102 are nested with each other by the first engaging portion 1011 and the second engaging portion 1021. The first housing 101 and the second housing 102 together define an accommodating space 11; the pet powder 20 is received in the accommodating space and is wrapped by the capsule container body 10, wherein the pet medicine powder 20 Containing 50% to 90% by weight of flavonoid compound and 10% to 50% by weight of d-limonene, the flavonoid compound is selected from the group consisting of naringin, hesperidin, neohesperidin, rutin, and orange pigment , chuanshensu, quercetin, artichoke glycosides, eriocitrin, new holy grass citrin, Preferably, the group consisting of 0.5% to 10% by weight of surfactant and 1% to 39.5% by weight of water, wherein the surfactant is HLB (hydrophilic-lipophilic balance) a value of 4 to 18 ethoxylated castor oil surfactant, more preferably, the ethoxylated castor oil surfactant has 1 to 200 carbon-carbon double bonds; in addition, a pet may be included The nutrient is mixed with the pet powder and placed in the accommodating space.

In practice, D-limonene can be added by adding allyl disulfide, citral, terpene, nerol, geraniol, carvacrol, eugenol, carvone, anethole, camphor, menthol, Limonene, myostatin, carotene, thymol, borneol, myrcene, terpenene, linalool, etc. The hydrazine can be obtained by a known technique such as a solvent extraction method, a distillation method or a chemical synthesis method.

In the present embodiment, the pet powder is composed of the following components: 17% by weight of d-limonene, 20% by weight of naringin, 15% by weight of hesperidin, 15% by weight of new hesperidin, 15% by weight of musk Glycoside, 10% by weight of quercetin, 1% by weight of other terpenoids, 2% by weight of surfactant, 5% by weight of water, the following experiment is carried out with the pet powder of this ingredient:

I. Antibacterial effect test: Prepare a sample liquid (5 mL) containing the above pet powder and a control solution (5 mL) which is homogenous to the sample liquid but does not contain the pet powder and is sterilized.

A 24-hour slant culture of test bacteria (S. aureus, Escherichia coli, Pseudomonas aeruginosa) was washed with phosphate buffered saline (PBS) to prepare a bacterial suspension (required concentration of 100 μL of bacterial suspension) When the amount was dropped in 5 mL of the control solution, the number of recovered bacteria was 1 × 10 ⁴ to 9 × 10 ⁴ cfu/mL.

100 μL of the bacterial suspension was added to each tube of the sample solution and the control solution, and 0.5 mL of each tube was added to a test tube containing 5 mL of PBS, thoroughly mixed and appropriately diluted, and then 0.5 mL was separately taken. As for the two culture dishes, 15 mL of the nutrient agar medium which had been cooled to 40-45 ° C was injected, and the culture dish was rotated to make it sufficiently uniform. The agar was solidified and then inverted, and cultured at 35 ° C ± 2 ° C for 48 hours as a live bacterial colony. count.

The test was repeated 3 times, and the inhibition rate was calculated according to the following formula: X = (AB) / A × 100% (where X is the inhibition rate (%), A is the average number of colonies of the control solution sample, and B is the sample solution. The average number of colonies in the sample).

The test results are shown in the table below:

It can be seen from the test results that the anti-bacterial rate of the pet powder of the present invention can reach 100% for the Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa which often cause bacterial dermatitis, and it is obvious that it has a good antibacterial effect.

2. Antifungal effect test: Prepare a sample liquid (5 mL) containing the above pet powder and a control solution (5 mL) which is homogenous to the sample liquid but does not contain the pet powder and is sterilized.

A 24-hour slant culture of test bacteria (Microsporum canis, Microsporum gypseum, Trichophyton mentagrophytes, Malassezia pachydermatis) was phosphate buffered The suspension was prepared by washing with physiological saline (PBS) (the required concentration was 100 μL of the suspension droplets in 5 mL of the control solution, and the number of recovered bacteria was 1 × 10 ⁴ to 9 × 10 ⁴ cfu/mL).

Add 100 μL of the suspension to each sample solution and the control solution, and then take 0.5 mL of each tube solution into a test tube containing 5 mL of PBS, mix well and dilute appropriately, and then separately absorb 0.5 mL. In two culture dishes, 15 mL of Sabouraud Dextrose Agar (SDA) which had been cooled to 40-45 ° C was injected, and the culture dish was rotated to make it fully uniform. The agar was solidified, inverted, and cultured at 35 ° C ± 2 ° C. Viable colonies were counted after 72 hours.

The test was repeated 3 times, and the inhibition rate was calculated according to the following formula: X = (AB) / A × 100% (where X is the inhibition rate (%), A is the average number of colonies of the control solution sample, and B is the sample solution. The average number of colonies in the sample).

The test results are shown in the following table:

It can be seen from the test results that the anti-bacterial rate of the pet powder of the present invention can reach 100 for the common fungal dermatitis and ear infections of Bacillus licheniformis, gypsum-like bacillus, hair fungus and dandruff spore. %, it is obvious that it has a good antibacterial effect.

3. Animal skin care toxicity test: Take 30 healthy mice (15 males and 15 females), weigh 120-150 g, shave the abdominal hair of each mouse into a square area of 2 cm × 2 cm, each mouse abdomen The skin is smooth, no abnormality, and has reference. The abdominal scraping area of each mouse was applied to the pet powder of the present invention, and it was applied three times a day for two weeks. After observation, there was no abnormality in the skin of the mouse, and no adverse symptoms were observed. Pet powder has no obvious toxicity.

IV. Oral toxicity test of animals: 30 healthy rats (15 males and 15 females) were taken from the experimental group and the control group, and the body weight was 450-520 g. Each rat in the experimental group was fed a daily dose of 1250 mg/kg of the pet powder, and the control group was kept in the usual manner for 13 weeks. No clinical symptoms or weight differences were observed between the two groups. Different from death, after humane happiness, no obvious pathological changes were observed by necropsy and microscopic examination. The results showed that the pet powder used in this creation had no obvious oral toxicity.

V. Clinical use cases: 24 cases of dogs with symptoms of bacterial or fungal dermatitis diagnosed by veterinarians with flushing, scaling, crusting, itching, hair loss and other symptoms on the face, lower neck, back, abdomen and tail roots. The age ranged from 6 months to 8 years old, and the body weight was 3 to 10 kilograms. The dogs were male and female. The disease, age, symptoms and hematological findings of the dogs were not significantly different, and they were comparable. The selected cases were divided into four groups (A, B, C, D). Group A used the pet powder for external use of the present application, sprayed twice daily on the affected part, and orally administered the pet powder 1000 mg/kg once daily. Group B uses the pet powder for external use of the present invention and sprays twice daily on the affected part; Group C orally prepares the pet powder 1000 mg/kg once daily; Group D is the control group, and commercialization is used. Antibiotics and antifungal oral medications, twice daily; experimental period 28 days.

The test results are as follows: (1) Significant effect: skin symptoms disappear, the affected area returns to normal; (2) effective: skin symptoms subsided by more than 30%; (3) invalid: skin symptoms subsided less than 30% or more serious; 4) Adverse reactions: Hematological examination results are different (below or higher than normal values) or side effects before the start of the experiment.

The experimental results are shown in the following table:

It can be seen from the above table that the efficiency of the pet powder used in this creation combined with oral treatment is as high as 100.0%, and no adverse reactions are observed. The therapeutic effect is obviously superior to the commonly used drugs, and has good clinical promotion significance.

In summary, the capsules containing the pet powder provided by the present invention have good effects against bacteria, antifungals, anti-inflammatory, etc., and have extremely low toxicity without side effects, and are quite suitable for clinical treatment and commercialization. It is a great help, and it is advantageous to prescribe, carry, feed and apply in a capsule container. It is important that the capsule container protects the pet powder from being destroyed before the stomach is absorbed to ensure the therapeutic effect.

Claims (6)

The capsule containing the pet powder comprises: a capsule container body, the capsule container body is composed of a first casing and a second casing, and the first casing and the second casing respectively have an opening. The first housing is hemispherical from the end far from the opening and the remaining portion is round tubular. The second housing is hemispherical from the end far from the opening and the remaining part is round tubular. The first housing is open at the opening. a first engaging portion is disposed on the side, the second housing has a second engaging portion beside the opening thereof, and the first housing and the second housing are sleeved with each other by the first engaging portion and the second engaging portion The first housing and the second housing together define an accommodating space; a pet powder is accommodated in the accommodating space and wrapped by the capsule container body. The capsule containing the pet powder according to claim 1, wherein the pet powder comprises 50% to 90% by weight of a flavonoid compound and 10% to 50% by weight of d-limonene, the flavonoid compound Choose from naringin, hesperidin, neohesperidin, rutin, orange pigment, chuanruin, quercetin, artichoke glycosides, eriocitrin, new licorice citrin, quercetin Group. The capsule containing the pet powder according to claim 2, wherein the pet medicament further comprises 0.5% to 10% by weight of a surfactant and 1% to 39.5% by weight of water. The capsule containing the pet powder according to claim 3, wherein the surfactant is an ethoxylated castor oil surfactant having an HLB value (hydrophilic-lipophilic balance) of 4 to 18. The capsule for pet powder according to claim 4, wherein the ethoxylated castor oil surfactant has from 1 to 200 carbon-carbon double bonds. The capsule containing the pet medicine powder according to any one of claims 1 to 5, further comprising a pet nutrition product, wherein the pet nutrition product is mixed with the pet medicine and then accommodated in the accommodating space.